US Patent 10,471,087: Scope of Claims, Claim-Strength Drivers, and US Landscape for TK2 Deficiency Using dC/dT
United States Patent 10,471,087 claims methods for treating thymidine kinase 2 (TK2) deficiency using a mixture of deoxycytidine (dC) and deoxythymidine (dT) administered at specified mg/kg/day exposure ranges, with claim-dependent coverage for dosing schedules, routes, formulation components, titration, monitoring, dose adjustment after adverse events, and optional add-on enzyme inhibitors.
What does the core independent claim cover?
Claim 1 is the primary independent claim and covers a treatment method with four essential elements:
- Indication: treating TK2 deficiency in a human subject in need thereof
- Agent: administering a composition comprising a mixture of dC and dT
- Exposure: a therapeutically effective amount of each deoxynucleoside in the range about 100 mg/kg/day to about 1000 mg/kg/day of each dC and dT
- Therapeutic framing: “therapeutically effective amount” is required, but the numeric bounds drive practice
Claim 3 is a second independent claim with a key scope shift:
- It requires the dose range to be about 100 mg/kg/day to about 1000 mg/kg/day of the total deoxynucleoside (combined dC+dT) rather than “each” nucleoside.
This “each vs total” distinction is the first major claim-construction lever for freedom-to-operate (FTO).
How broad is the dose coverage (each vs total)?
The patent’s dose architecture creates two overlapping but not identical protected bands.
Claim 1 dose band (each nucleoside)
- 100 to 1000 mg/kg/day of dC
- 100 to 1000 mg/kg/day of dT
- Exposure is specified per deoxynucleoside
Claim 3 dose band (total nucleoside)
- 100 to 1000 mg/kg/day total for dC+dT
Practical implication for product design
- A regimen giving total exposure within the Claim 3 band but pushing one component above the Claim 1 “each” band may fall outside Claim 1 while still falling inside Claim 3.
- Conversely, a regimen with both dC and dT each within Claim 1 does not automatically guarantee the total is within Claim 3 unless the sum falls in the total band.
This makes the exact formulation ratio and dosing target essential to risk mapping.
What dosing schedules and routes expand claim coverage?
Claims 4, 5, 6 expand operational scope beyond “dose only.”
Dosing frequency (Claim 4)
Composition administration can be:
- once daily
- twice daily
- three times daily
- four times daily
- five times daily
- six times daily
This is broad across standard oral and parenteral regimens.
Routes (Claim 5)
Administration can be:
- oral
- intrathecal
- enteral
- intravenous
Oral liquid/composition environment (Claim 6)
If administered orally, the composition further comprises one or more of:
- cow’s milk
- human breast milk
- infant formula
- water
That language can capture an oral dosing form regardless of whether the key actives are dissolved, suspended, or otherwise presented in these carrier matrices, depending on how “comprises” is construed.
What adjunct therapy coverage exists?
Claim 7 adds another layer of combination therapy:
- Further comprising an additional agent chosen from:
- inhibitor of thymidine phosphorylase
- inhibitor of cytidine deaminase
This is not limited to any specific compound identity in the text provided, but it does impose a category requirement if an accused regimen includes add-on enzyme inhibition.
How does the patent cover titration and dose escalation/de-escalation?
The claims build a controlled dosing algorithm rather than a single static dose.
Increased over time (Claims 8, 9, 20, 21)
- Claim 8: therapeutically effective amount increased over time
- Claim 9: provides an explicit stepping example:
- first amount about 100 mg/kg/day of each deoxynucleoside
- then increased over time to 200, 400, 800, up to 1000 mg/kg/day of each
Claim 20 and 21 mirror these concepts but tie to Claim 3’s “composition” dose logic (each vs total differences are reflected by the claim dependency structure).
Monitoring-based adjustment (Claims 10-13)
Claim 10 defines monitoring steps after administration:
- observe muscle strength and control
- observe differences in height and weight
- observe mobility
- determine improvement if any of (a)-(c) increased after administration
- determine no improvement if any of (a)-(c) are the same or decreased
Claim 11: if “no improvement” is determined, then the effective amount is increased.
Claim 12: monitoring for adverse effect
- if adverse effect is observed, decrease the effective amount
Claim 13: if adverse effect persists? (by language provided)
- after decrease, if adverse effect is no longer observed, the effective amount is increased
This generates protected practice for clinicians operating a titration loop keyed to clinical response and tolerability.
Mirrored monitoring for Claim 3 (Claims 26-29)
Claims 26-29 repeat the same monitoring schema for the “total nucleoside” framework.
What about narrower numeric sub-ranges?
Several dependent claims carve narrower protected ranges, tightening the exposure band if a competitor targets a mid-range dose:
- Claim 14: 250 to 400 mg/kg/day of each nucleoside (each dC and dT)
- Claim 15: 100 to 400 mg/kg/day of each nucleoside
- Claim 16: Claim 3 total framework: 200 to 800 mg/kg/day total
- Claim 17: Claim 3 total framework: 250 to 400 mg/kg/day total
These sub-ranges matter when assessing design-around risk. A regimen at the high end of the broad band may still sit outside some narrower dependent claims but can still infringe the independent base claims if within their wide ranges.
What is the patent’s claim scope on dC:dT ratios?
Claim 18 gives a detailed set of permissible ratio options:
- dC:dT ratios include:
50/50, 5/95, 10/90, 15/85, 20/80, 25/75, 30/70, 35/65, 40/60, 45/55, 55/45, 60/40, 65/35, 70/30, 75/25, 80/20, 85/15, 90/10, 95/5
Claim 19 narrows explicitly to 50/50.
Claim dependency implies:
- the base independent claim already requires a mixture of dC and dT
- the ratio claims add explicit enumerated composition ratios that can prevent easy design-around by adjusting relative amounts unless the ratio is outside the enumerated set (not all possible ratios are listed in the provided text, but “wherein ratio is” claims suggest the enumerated ratios are the protected ones at that dependency level)
Risk mapping depends on whether a competitor uses:
- a ratio inside the enumerated list
- or an unlisted ratio (if “ratio is” is construed strictly)
How is claim coverage structured across “each” vs “total” and monitoring variants?
The provided claims indicate a mirrored set between Claim 1 and Claim 3:
| Claim Set Theme |
Claim 1/Dependent Claims |
Claim 3/Dependent Claims |
| Independent method |
Claim 1 |
Claim 3 |
| Dose basis |
“each deoxynucleoside” |
“total deoxynucleoside” |
| Frequency and routes |
Claims 4-6 |
Claims 22-24 |
| Enzyme inhibitors add-on |
Claim 7 |
Claim 25 |
| Escalation over time |
Claims 8-9 |
Claims 20-21 |
| Monitoring for response |
Claims 10-11 |
Claims 26-27 |
| Monitoring for adverse effects |
Claims 12-13 |
Claims 28-29 |
| Dose sub-bands |
Claims 14-15 |
Claims 16-17 |
| Ratio options |
Claims 18-19 |
Claims 30-31 |
This creates two parallel infringement “tracks.” A regimen that avoids Claim 1 may still land in Claim 3 depending on whether dosing is expressed and administered as total vs per-component mg/kg/day in a manner consistent with claim language.
What is the patent landscape risk profile in the US for dC/dT in TK2 deficiency?
Landscape drivers (based on claim content you provided)
The patent’s scope indicates enforcement likely centers on:
- Treatment of TK2 deficiency using dC/dT
- Numeric dosing within wide mg/kg/day bands
- Combination or titration protocol (monitoring and dose adjustment)
- Routes including oral and intrathecal
- Ratio flexibility within enumerated ranges
- Optional enzyme inhibitor co-therapy categories
Where enforcement leverage is highest
Higher likelihood of enforcement attaches to regimens that match multiple protected dimensions simultaneously:
- TK2 deficiency patient population
- mixture of dC and dT
- within broad dose bands
- administered at common oral frequencies and/or intrathecal route
- and using titration and monitoring steps consistent with the claims.
If an accused regimen omits titration/monitoring steps, it still can infringe the method claims if the infringement theory is solely the administration of the composition at a claimed exposure band. The monitoring elements are embedded in dependent claims, so omissions may avoid those dependent claim coverages, but not the independent base.
Design-around pressure points created by the claims
The claim set creates potential design-around variables:
- targeting a dose that stays outside “each” range for Claim 1 but inside total range for Claim 3 (or vice versa)
- selecting a ratio not enumerated in the ratio claims (for dependent claim risk)
- using routes not covered (though the route list is extremely broad)
- avoiding explicit addition of enzyme inhibitor categories
- using different clinical adjustment criteria (to avoid dependent monitoring claims)
Freedom-to-operate mapping: how claims typically intersect competitor programs
1) Oral pediatric formulations (milk/formula/water)
Claim 6 pulls oral carrier vehicles into scope. Any oral dC/dT dosing that uses cow’s milk, breast milk, infant formula, or water as a component in the composition can match this dependent claim layer.
2) Intrathecal and IV programs
Claim 5 covers intrathecal and IV, which makes route-based design-around less effective. Many TK2 programs that pursue CNS delivery via intrathecal dosing face direct overlap with the claim language.
3) Combination with enzyme inhibitors
Claim 7 and Claim 25 cover add-on thymidine phosphorylase and cytidine deaminase inhibitors as categories. If a program co-administers one of these inhibitor classes, it is closer to dependent claim coverage.
4) Titration protocols
Claims 8-9, 20-21, 10-13, 26-29 can align with real-world clinical titration where dosing is escalated based on response and decreased for adverse events. This increases infringement risk for method claims structured to match a protocolized clinical workflow.
Key Takeaways
- US 10,471,087 protects TK2 deficiency treatment via administering a dC/dT mixture with dosing defined both as per-component (“each”) in Claim 1 and as combined (“total”) in Claim 3.
- Dependent claims broaden practice to all common dosing frequencies (up to six times daily) and multiple administration routes including oral, intrathecal, enteral, and intravenous.
- The patent adds scope for oral carrier compositions (milk, breast milk, infant formula, water), optional enzyme inhibitor co-therapy (thymidine phosphorylase or cytidine deaminase inhibitors), and protocolized dose adjustment driven by muscle strength/mobility/height-weight observations and adverse event monitoring.
- Numeric narrowing exists for mid-range dosing bands (e.g., 250-400 mg/kg/day of each and 250-400 mg/kg/day total) and for specific enumerated dC:dT ratios, creating multiple claim layers that can be hard to avoid if a program tracks clinical precedent.
- Landscape enforcement risk is highest where accused regimens match multiple axes at once: indication (TK2), dC/dT mixture, dose band, route, and titration/monitoring workflow.
FAQs
-
Does the patent require a specific dC:dT ratio?
Independent claims require a mixture of dC and dT; dependent claims specify enumerated ratios, including 50/50 and multiple asymmetric splits.
-
What is the biggest structural difference between Claim 1 and Claim 3?
Claim 1 limits dosing to mg/kg/day of each nucleoside, while Claim 3 limits dosing to mg/kg/day of total nucleoside (dC+dT).
-
Can dosing be intrathecal under this patent?
Yes. Dependent coverage includes intrathecal administration.
-
Does the patent protect clinician titration based on patient outcomes?
Yes. Dependent claims require monitoring muscle strength/control, height/weight, and mobility to determine improvement, plus adverse-effect monitoring to guide dose increase or decrease.
-
Is combination therapy with enzyme inhibitors covered?
Yes. Dependent claims include add-on agents that are inhibitors of thymidine phosphorylase or cytidine deaminase.
References
[1] United States Patent No. 10,471,087.
